Paricalcitol effects on activities and metabolism of platelet activating factor and on inflammatory cytokines in hemodialysis patients

International Journal of Artificial Organs

Volumn 36, Issue 2, 2013, Pages 87-96

  Verouti, Sophia N ^a   Tsoupras, Alexandros B ^a   Alevizopoulou, Fotini ^b   Demopoulos, Constantinos A ^a   Iatrou, Christos ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

Author keywords

Cytokines; Hemodialysis; PAF; Paricalcitol; Thrombin

Indexed keywords

CELLS; DIALYSIS; HEMODIALYZERS; METABOLISM; PATIENT TREATMENT; PLATELETS; VITAMINS;

BLOOD CELLS; CYTOKINES; HAEMODIALYSIS; HEMODIALYSIS PATIENT; IN-VITRO; INFLAMMATORY MEDIATORS; LEUCOCYTES; PAF; PARICALCITOL; TNF Α;

ENZYMES;

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; 1 O ALKYLGLYCERO 3 PHOSPHORYLCHOLINE; ACYLTRANSFERASE; CHOLESTEROL; CHOLINEPHOSPHOTRANSFERASE; CYTIDINE DIPHOSPHATE; CYTOKINE; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYSOSOME ENZYME; PARICALCITOL; THROMBIN; THROMBOCYTE ACTIVATING FACTOR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D;

ARTICLE; BIOASSAY; CELL ISOLATION; CHRONIC KIDNEY DISEASE; ENZYME ACTIVITY; ERYTHROCYTE; FLOW CYTOMETRY; HEMODIALYSIS; HUMAN; HUMAN CELL; INFLAMMATION; LEUKOCYTE; PLASMA; THROMBOCYTE; THROMBOCYTE AGGREGATION;

EID: 84874850596     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.5301/ijao.5000187     Document Type: Article

References (46)

1. Del Valle E, Negri AL, Aguirre C, Fradinger E, Zanchetta JR. Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis. Hemodial Int. 2007;11(3):315-321.
2. Uhlig K, Sarnak MJ, Singh AK. New approaches to the treatment of calcium and phosphorus abnormalities in patients on hemodialysis. Curr Opin Nephrol Hypertens. 2001;10(6): 793-798.
3. Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis. 2011;58(3):374-382.
4. Wu-Wong JR, Nakane M, Traylor L, Ruan X, Kroeger PE, Tian J. Cardiovascular disease in chronic kidney failure: is there a role for vitamin D analogs? Curr Opin Investig Drugs. 2005; 6(3):245-254.
5. Petchey WG, Johnson DW, Isbel NM. Shining D' light on chronic kidney disease: mechanisms that may underpin the cardiovascular benefit of vitamin D. Nephrology (Carlton). 2011;16(4):351-367.
6. Ogawa T, Kyono A, Sato M, Sugimoto H, Otsuka K, Nitta K. Vitamin D receptor agonist supplementation and suppression of inflammation may have advantage for all-cause mortality in hemodialysis patients. Clin Exp Nephrol. 2012; 16(5):779-785.
7. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003;349(5):446-456.
8. Tetta C, David S, Biancone L, Canino F, Cambi V, Camussi G. Role of platelet activating factor in hemodialysis. Kidney Int Suppl. 1993;39:S154-S157.
9. Perico N, Remuzzi G. Role of platelet-activating factor in renal immune injury and proteinuria. Am J Nephrol. 1990; 10(Suppl 1):98-104.
10. Camussi G, Tetta C, Bussolino F, Andres G, Turello E, Baglioni C. Involvement of cytokines and platelet-activating factor in renal pathology. J Lipid Mediat. 1990;2(Suppl):S203-S213.
11. Iatrou C, Afentakis N, Antonopoulou S, Andrikopoulos N, Demopoulos CA, Ziroyannis P. The production of plateletactivating factor (PAF) during hemodialysis with cuprophane membrane. Does the calcium concentration in the dialysate play any role on it? Int J Artif Organs. 1995;18(7): 355-361.
12. Iatrou C, Afentakis N, Nomikos T, Dinas C, Stavropoulos-Giokas C, Antonopoulou S. Is platelet-activating factor produced during hemodialysis with AN-69 polyacrylonitrile membrane? Nephron. 2002;91(1):86-93.
13. Demopoulos CA, Pinckard RN, Hanahan DJ. Plateletactivating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem. 1979;254 (19):9355-9358.
14. Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med. 2002;30(5)(Suppl):S294-S301.
15. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM. Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit Rev Clin Lab Sci. 2003;40(6):643-672.
16. Demopoulos CA, Karantonis HC, Antonopoulou S. Platelet activating factor-a molecular link between atherosclerosis theories. Eur J Lipid Sci Technol. 2003;105(11):705-716.
17. Snyder F. Platelet-activating factor: the biosynthetic and catabolic enzymes. Biochem J. 1995;305(Pt 3):689-705.
18. Silverstein DM. Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. Pediatr Nephrol. 2009;24(8):1445-1452.
19. Cappelli G, DiFelice A, Perrone S, et al. Which level of cytokine production is critical in haemodialysis? Nephrol Dial Transplant. 1998;13(Suppl 7):55-60.
20. Stenvinkel P, Ketteler M, Johnson RJ, et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int. 2005;67(4):1216-1233.
21. Bussolino F, Sironi M, Bocchietto E, Mantovani A. Synthesis of platelet-activating factor by polymorphonuclear neutrophils stimulated with interleukin-8. J Biol Chem. 1992; 267(21):14598-14603.
22. Bussolino F, Camussi G, Tetta C, Garbarino G, Bosia A, Baglioni C. Selected cytokines promote the synthesis of platelet-activating factor in vascular endothelial cells: comparison between tumor necrosis factor alpha and beta and interleukin-1. J Lipid Mediat. 1990;2(Suppl):S15-S22.
23. Nasu K, Narahara H, Matsui N, Kawano Y, Tanaka Y, Miyakawa I. Platelet-activating factor stimulates cytokine production by human endometrial stromal cells. Mol Hum Reprod. 1999;5(6):548-553.
24. Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int. 2006;69(1):33-43.
25. Chen SF. 1 alpha, 25-Dihydroxyvitamin D3 decreased ICAM-1 and ELAM-1 expressions on pulmonary microvascular endothelial cells and neutrophil motivation. J Steroid Biochem Mol Biol. 1995;52(1):67-70.
26. Fragopoulou E, Nomikos T, Karantonis HC, et al. Biological activity of acetylated phenolic compounds. J Agric Food Chem. 2007;55(1):80-89.
27. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
28. Tsoupras AB, Fragopoulou E, Nomikos T, Iatrou C, Antonopoulou S, Demopoulos CA. Characterization of the de novo biosynthetic enzyme of platelet activating factor, DDTinsensitive cholinephosphotransferase, of human mesangial cells. Mediators Inflamm. 2007;2007:27683.
29. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37(8):911-917.
30. Tsoupras AB, Chini M, Tsogas N, et al. Anti-plateletactivating factor effects of highly active antiretroviral therapy (HAART): a new insight in the drug therapy of HIV infection? AIDS Res Hum Retroviruses. 2008;24(8):1079-1086.
31. Antonopoulou S, Demopoulos CA, Iatrou C, Moustakas G, Zirogiannis P. Platelet-activating factor acetylhydrolase (PAFAH) in human kidney. Int J Biochem. 1994;26(9):1157-1162.
32. Morgan E, Varro R, Sepulveda H, et al. Cytometric bead array: a multiplexed assay platform with applications in various areas of biology. Clin Immunol. 2004;110(3):252-266.
33. Heuer HO. Involvement of platelet-activating factor (PAF) in septic shock and priming as indicated by the effect of hetrazepinoic PAF antagonists. Lipids. 1991;26(12):1369-1373.
34. Fletcher JR, DiSimone AG, Earnest MA. Platelet activating factor receptor antagonist improves survival and attenuates eicosanoid release in severe endotoxemia. Ann Surg. 1990;211(3):312-316.
35. Izquierdo I, Merlos M, García-Rafanell J. Rupatadine: a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. A review of pharmacological profile and clinical management of allergic rhinitis. Drugs Today (Barc). 2003;39(6):451-468.
36. Tsantila N, Tsoupras AB, Fragopoulou E, Antonopoulou S, Iatrou C, Demopoulos CA. In vitro and in vivo effects of statins on platelet-activating factor and its metabolism. Angiology. 2011;62(3):209-218.
37. Agmon-Levin N, Blank M, Zandman-Goddard G, et al. Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis. 2011;70(1):145-150.
38. Beer TM, Venner PM, Ryan CW, et al. High dose calcitriol may reduce thrombosis in cancer patients. Br J Haematol. 2006;135(3):392-394.
39. Detopoulou P, Nomikos T, Fragopoulou E, et al. Platelet activating factor (PAF) and activity of its biosynthetic and catabolic enzymes in blood and leukocytes of male patients with newly diagnosed heart failure. Clin Biochem. 2009;42(1-2):44-49.
40. Khovidhunkit W, Memon RA, Shigenaga JK, et al. Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Metabolism. 1999;48(12):1524-1531.
41. Iatrou C, Moustakas G, Antonopoulou S, Demopoulos CA, Ziroyiannis P. Platelet-activating factor levels and PAF acetylhydrolase activities in patients with primary glomerulonephritis. Nephron. 1996;72(4):611-616.
42. Asano K, Okamoto S, Fukunaga K, et al. Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. Biochem Biophys Res Commun. 1999;261(2):511-514.
43. Papavasiliou EC, Gouva C, Siamopoulos KC, Tselepis AD. Erythrocyte PAF-acetylhydrolase activity in various stages of chronic kidney disease: effect of long-term therapy with erythropoietin. Kidney Int. 2005;68(1):246-255.
44. Pereira BJ, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA. Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int. 1994;45(3):890-896.
45. Stubbs JR, Idiculla A, Slusser J, Menard R, Quarles LD. Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol. 2010;21(2):353-361.
46. Panichi V, De Pietro S, Andreini B, et al. Calcitriol modulates in vivo and in vitro cytokine production: a role for intracellular calcium. Kidney Int. 1998;54(5):1463-1469.